Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Charles M. Ponthier"'
Autor:
Jian An, Charles M. Ponthier, Ragna Sack, Jan Seebacher, Michael B. Stadler, Katherine A. Donovan, Eric S. Fischer
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
Targeting therapeutically-relevant proteins for degradation is an emerging paradigm in drug discovery. Here the authors describe a sensitive pulse SILAC mass spectrometry-based proteomics approach that reports global changes in protein stability foll
Externí odkaz:
https://doaj.org/article/29e7aa9bcbbf457cab317eff9b4c1bbd
Autor:
Brian H. White, Yaguang Si, Sarah Cappucci, Zhi Li, Jessica D. Ramirez, Charles M. Ponthier, Erica Visness, Peicheng Du, Minjung Choi, Pieter C. Beerepoot, Paula C. Ortet, Ivan T. Jewett, Josue Alfaro-Lopez, Sorabh Agarwal, Daniel La, Aaron Fulgham, John H. McGee, Keith Orford, Jonathan B. Hurov, Martin R. Tremblay, Gregory L. Verdine
Publikováno v:
Cancer Research. 83:3094-3094
Wnt signaling pathway mutations leading to constitutive activation of the driver oncogene β-catenin occur in at least 20% of all human cancers, but β-catenin itself has remained undruggable by traditional modalities. In order to inhibit the activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c51d264aae8f3a219530f16aa966065
https://doi.org/10.1158/1538-7445.am2023-3094
https://doi.org/10.1158/1538-7445.am2023-3094
Autor:
Jaebong Jang, Ciric To, Dries J. H. De Clercq, Eunyoung Park, Charles M. Ponthier, Bo Hee Shin, Mierzhati Mushajiang, Radosław P. Nowak, Eric S. Fischer, Michael J. Eck, Pasi A. Jänne, Nathanael S. Gray
Publikováno v:
Angewandte Chemie. 132:14589-14597
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25323c82c1bd4d31e476eeb4c4fb5087
https://doi.org/10.1002/ange.202003500
https://doi.org/10.1002/ange.202003500
Autor:
Bo Hee Shin, Dries De Clercq, Charles M. Ponthier, Jaebong Jang, Nathanael S. Gray, Ciric To, Radosław P. Nowak, Pasi A. Jänne, Eric S. Fischer, Eun Young Park, Michael J. Eck, Mierzhati Mushajiang
Publikováno v:
Angew Chem Int Ed Engl
Targeting epidermal growth factor receptor (EGFR) through an allosteric mechanism provides a potential therapeutic strategy to overcome drug-resistant EGFR mutations that emerge within the ATP binding site. Here, we develop an allosteric EGFR degrade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d89bbbd0e883d285550c1187d06323d
https://europepmc.org/articles/PMC7686272/
https://europepmc.org/articles/PMC7686272/
Autor:
Katherine A. Donovan, Charles M. Ponthier, Ragna Sack, Jan Seebacher, Michael B. Stadler, Eric S. Fischer, Jian An
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-11 (2017)
Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of haematologic malignancies. It was shown that IMiDs impart gain-of-function properties to the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase that enable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b823fce410ca4d850e7ed97e8c58b6b
https://doaj.org/article/29e7aa9bcbbf457cab317eff9b4c1bbd
https://doaj.org/article/29e7aa9bcbbf457cab317eff9b4c1bbd
Autor:
Charles M. Ponthier, Radosław P. Nowak, Eric S. Fischer, Nozhat Safaee, Jian An, James E. Bradner, Mette Ishoey, Dennis L. Buckley, Zhixiang He, Stephen L. DeAngelo, Nathanael S. Gray, Katherine A. Donovan, Joseph D. Mancias, Tinghu Zhang, Mark P. Jedrychowski
Publikováno v:
Nature chemical biology
SUMMARY Heterobifunctional small molecule degraders that induce protein degradation through ligase-mediated ubiquitination have shown considerable promise as a new pharmacological modality. However, we currently lack a detailed understanding of the m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc45b5a1dea1b9e872e614dd7cd1bc07
https://pubmed.ncbi.nlm.nih.gov/29892083
https://pubmed.ncbi.nlm.nih.gov/29892083
Autor:
Jian, An, Charles M, Ponthier, Ragna, Sack, Jan, Seebacher, Michael B, Stadler, Katherine A, Donovan, Eric S, Fischer
Publikováno v:
Nature Communications
Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of haematologic malignancies. It was shown that IMiDs impart gain-of-function properties to the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase that enable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d1221110eb8ee7cd742df421acc7c025
https://pubmed.ncbi.nlm.nih.gov/28530236
https://pubmed.ncbi.nlm.nih.gov/28530236